GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Intravenous Infusions Ltd (XGHA:IIL) » Definitions » Debt-to-Equity

Intravenous Infusions (XGHA:IIL) Debt-to-Equity : 0.00 (As of . 20)


View and export this data going back to 2015. Start your Free Trial

What is Intravenous Infusions Debt-to-Equity?

Intravenous Infusions's Short-Term Debt & Capital Lease Obligation for the quarter that ended in . 20 was GHS0.00 Mil. Intravenous Infusions's Long-Term Debt & Capital Lease Obligation for the quarter that ended in . 20 was GHS0.00 Mil. Intravenous Infusions's Total Stockholders Equity for the quarter that ended in . 20 was GHS0.00 Mil.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Intravenous Infusions's Debt-to-Equity or its related term are showing as below:

XGHA:IIL's Debt-to-Equity is not ranked *
in the Drug Manufacturers industry.
Industry Median: 0.3
* Ranked among companies with meaningful Debt-to-Equity only.

Intravenous Infusions Debt-to-Equity Historical Data

The historical data trend for Intravenous Infusions's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Intravenous Infusions Debt-to-Equity Chart

Intravenous Infusions Annual Data
Trend
Debt-to-Equity

Intravenous Infusions Semi-Annual Data
Debt-to-Equity

Competitive Comparison of Intravenous Infusions's Debt-to-Equity

For the Drug Manufacturers - Specialty & Generic subindustry, Intravenous Infusions's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Intravenous Infusions's Debt-to-Equity Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Intravenous Infusions's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Intravenous Infusions's Debt-to-Equity falls into.



Intravenous Infusions Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Intravenous Infusions's Debt to Equity Ratio for the fiscal year that ended in . 20 is calculated as

Intravenous Infusions's Debt to Equity Ratio for the quarter that ended in . 20 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Intravenous Infusions  (XGHA:IIL) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.


Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.


Intravenous Infusions Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Intravenous Infusions's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


Intravenous Infusions Business Description

Traded in Other Exchanges
N/A
Address
Plot 4/7 Blk L, P.O Box KF 63, Effiduase-Koforidua, GHA
Intravenous Infusions Ltd engages in the production of intravenous infusion and small-volume injectables for therapeutic purposes. The product categories are IV fluids, giving sets, and small-volume injectables. The company earns a majority of its revenue from IV fluids. Some of the IV fluids are sodium chloride solutions, dextrose solutions, dextrose saline solutions, and dextran solutions. Small-volume injectables include pethidine injection, magnesium sulphate injection, and quinine injection. Giving sets include plain giving sets, and blood giving sets.